Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2016-11-28 Report Publication Anno…
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document is a press release announcing that the company management will participate in a specific external investor conference (Guggenheim Securities 4th Annual Boston Healthcare Conference) and hold one-on-one meetings. This type of announcement, which details management's schedule for meeting investors, is typically classified as an Investor Presentation or general Investor Relations activity, but given the specific options, it most closely aligns with an announcement related to investor engagement. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a proxy statement (DEF 14A, PSI), nor a management discussion (MDA), the best fit among the provided codes for an announcement focused on management meeting investors to present the pipeline is Investor Presentation (IP), as these announcements often precede or accompany such presentations. However, a more precise classification for an announcement about *attending* a conference is often a general Regulatory Filing (RNS) or sometimes an Investor Relations (IR) document if IR was an option. Given the options, and recognizing this is an announcement about future investor engagement rather than the presentation material itself, RNS (Regulatory Filings/General Announcement) is a strong candidate, but IP covers investor-facing events. Since the content is purely promotional/informational about management availability at a conference, and not a formal report, I will lean towards RNS as the most appropriate general regulatory announcement category for non-standard investor updates, or IP if we interpret 'Investor Presentation' broadly to include announcements about investor meetings. Given the context of financial databases, announcements about management roadshows/conferences are often grouped under general IR announcements. I will select RNS as the safest general regulatory announcement category for this type of press release.
2016-11-28 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is a press release dated November 28, 2016, announcing that the management of Onxeo S.A. will meet with investors at the 4th Annual Guggenheim Securities Healthcare Conference on December 13, 2016. The content focuses on the company's strategy, product pipeline, and the opportunity to meet with management at a specific industry event. This type of announcement, detailing participation in an investor conference where management will present strategy and meet investors, aligns best with the 'Investor Presentation' (IP) category, as it is preparatory material or an announcement related to investor engagement and presentation of company information, even if the presentation itself is not fully included. It is not a formal regulatory filing like 10-K or IR, nor is it a simple earnings release (ER) or a report publication announcement (RPA). It is specifically about engaging with investors at a conference.
2016-11-28 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release titled "Onxeo Announces 9th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC". It details an operational update regarding a clinical trial (Phase III) and the positive recommendation from the Data Safety Monitoring Board (DSMB). This type of announcement, focusing on clinical trial progress, safety data review, and operational milestones, is typically classified as an Earnings Release (ER) if it contains key financial highlights, or more generally, a Regulatory Filing (RNS) if it's a specific operational update that doesn't fit other categories. Since it is an announcement of a specific operational event (DSMB recommendation) rather than a full financial report (10-K, IR) or a management discussion (MDA), and it is not a proxy statement (DEF 14A) or a dividend notice (DIV), the most appropriate category among the provided options for a significant, non-financial-results-focused operational update is often the general Regulatory Filing (RNS), or potentially an Earnings Release (ER) if it's part of the regular cycle, though it lacks explicit quarterly results. Given the focus is purely on trial continuation and safety, and it's a press release format, RNS is the safest general classification for non-standard operational news, although ER is also plausible if this is considered part of the regular reporting cadence. However, since it is a specific, non-financial-result-driven operational update, I will classify it as RNS (Regulatory Filings) as the best fit for miscellaneous regulatory/operational announcements not covered elsewhere.
2016-11-21 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo dated November 21, 2016, announcing a positive recommendation from the Data Safety Monitoring Board (DSMB) to continue its Phase III clinical trial ('ReLive') for the drug Livatag® in liver cancer. This type of announcement, detailing clinical trial progress, safety data review, and future outlook (e.g., expected preliminary results in mid-2017), is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a specific announcement about operational/clinical progress rather than a formal financial report (like 10-K or IR) or a management discussion (MDA), and it is not a transcript (CT) or a formal regulatory filing notice (RPA/RNS), the most fitting category is Earnings Release (ER), as these often include key operational milestones alongside financial highlights, or it could be classified as a Regulatory Filing (RNS) if it were purely regulatory. Given the focus on trial progress and the structure of a press release, ER is often used for such operational updates, but since it is not explicitly reporting quarterly/periodical financial results (it's a clinical update), and it doesn't fit other specific categories like LTR (Legal) or CAP (Financing), it falls best under the general Regulatory Filings (RNS) category as a significant corporate announcement that doesn't fit the more specific operational/financial codes. However, looking closely at the definitions, this is a specific operational update about a drug trial, which often accompanies or precedes an ER. Since it is a formal announcement of a significant corporate event (clinical trial status), and not a general regulatory filing fallback, I will re-evaluate. It is not a DEF 14A (Remuneration), not a DIV (Dividend), not an IP (Investor Presentation). It is a material corporate event announcement. In many databases, significant clinical trial updates are categorized under RNS (Regulatory Filings) if they don't have a dedicated clinical trial code. Given the options, RNS serves as the best catch-all for material, non-financial, non-management change announcements.
2016-11-21 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
AGM Information Classification · 1% confidence The document is a press release from Onxeo announcing its participation in the Actionaria trade show on November 18th and 19th, 2016. It details the schedule of presentations and shareholder meetings during the event. This type of announcement, which informs the public about the company's presence or schedule at an industry event, does not fit the definitions for formal financial reports (10-K, IR, ER, MRQ) or specific corporate actions (DIV, CAP, DIRS). It is a general corporate update related to investor relations and corporate events. Since it is not a transcript (CT), a formal presentation (IP), or a specific regulatory filing like a Director's Dealing or Dividend notice, the most appropriate general category for miscellaneous corporate announcements that don't fit elsewhere is 'Regulatory Filings' (RNS), as it serves as a general announcement mechanism.
2016-11-08 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated November 4, 2016, announcing 'Promising Results from Preclinical Studies of Livatag® in Pancreatic Cancer.' It details scientific findings, quotes the CSO, and provides company background and contact information. This type of announcement, focusing on scientific progress or preliminary data outside of mandated periodic financial reports (like 10-K or IR), is typically classified as a general corporate or investor relations communication. Since it is not a formal Earnings Release (ER), a Call Transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ), it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for corporate news releases that don't fit elsewhere, or potentially as an Investor Presentation (IP) if it were structured as slides, but given the format, RNS is the most appropriate general classification for corporate news updates.
2016-11-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.